SLC9A2 and neoplasm: Following a 10-day period of subcutaneous tumor implantation, mice received two weeks of intratumoral injections of either the Slc9a2 overexpression plasmid vector plus delivery buffer or the control vector plus delivery buffer, with bevacizumab serving as a positive control.